Pharmacure Nozoil 10ml

Product Information

In the placebo-controlled studies, fold increase in peripheral blood CD34+ cell count (cells/μl) over the 24-hour period from the day prior to the first apheresis to just before the first apheresis was evaluated (Table 7). During that 24-hour period, the first dose of plerixafor 0.24 mg/kg or placebo was administered 10-11 hours prior to apheresis. If you are using another nasal product, apply Flo Nozoil at least 20 minutes afterwards. For further information, please refer to your healthcare practitioner. Are there any side effects when using Flo Nozoil? Based on increasing exposure with increasing body weight the dose should not exceed 27 mg/day if the creatinine clearance is lower than 50 ml/min. In pharmacodynamic studies in healthy volunteers of plerixafor alone, peak mobilisation of CD34+ cells was observed from 6 to 9 hours after administration. In pharmacodynamic studies in healthy volunteers of plerixafor in conjunction with G-CSF administered at identical dose regimen to that in studies in patients, a sustained elevation in the peripheral blood CD34+ count was observed from 4 to 18 hours after plerixafor administration with peak response between 10 and 14 hours. Plerixafor is moderately bound to human plasma proteins up to 58%. The apparent volume of distribution of plerixafor in humans is 0.3 l/kg demonstrating that plerixafor is largely confined to, but not limited to, the extravascular fluid space.

In Mozobil clinical studies of oncology patients, there have been rare reports of severe gastrointestinal events, including diarrhoea, nausea, vomiting, and abdominal pain. Put the tip of the pump into one nostril. Hold the bottle upright and pump two to three times. Change the direction of the spray so that the oil reaches different parts of the mucosa. Inhale at the same time. The oil leaves the bottle in a fine spray and not as a cloud of spray. Dry the tip of the bottle after use and replace the plastic cap. It protects the oil from air and foreign particles that could contaminate the contents. Flo Nozoil is not recommended for children under 4 years of age, unless advised by a healthcare practitioner. PrecautionsThrombocytopenia is a known complication of apheresis and has been observed in patients receiving Mozobil. Platelet counts should be monitored in all patients receiving Mozobil and undergoing apheresis. Flo Nozoil helps relieve dry and crusting nasal tissue. Your healthcare practitioner may recommend Nozoil in the following situations: Administration of Mozobil in conjunction with G-CSF increases circulating leukocytes as well as haematopoietic stem cell populations. White blood cell counts should be monitored during Mozobil therapy. Clinical judgment should be exercised when administering Mozobil to patients with peripheral blood neutrophil counts above 50 x 10 9/L. In preclinical studies, higher absolute and relative spleen weights associated with extramedullary haematopoiesis were observed following prolonged (2 to 4 weeks) daily plerixafor subcutaneous administration in rats at doses approximately 4 fold higher than the recommended human dose.

Patients with creatinine clearance 20-50 ml/min should have their dose of plerixafor reduced by one-third to 0.16 mg/kg/day (see section 5.2). Clinical data with this dose adjustment are limited. There is insufficient clinical experience to make alternative posology recommendations for patients with a creatinine clearance <20 ml/min, as well as to make posology recommendations for patients on haemodialysis. Mozobil therapy should be initiated and supervised by a physician experienced in oncology and/or haematology. The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed. The use of Rinaspray has not been evaluated in children, and therefore is not recommended for use in patients below the age of 12 years.In Mozobil oncology and healthy volunteer clinical studies, less than 1% of subjects experienced vasovagal reactions (orthostatic hypotension and/or syncope) following subcutaneous administration of plerixafor doses ≤0.24 mg/kg. The majority of these events occurred within 1 hour of Mozobil administration. Patients who undergo radiation treatment on the head and throat often experience problems with dry mucous membranes that are damaged by the radiation for a long time after the treatment. Dry air makes it easier for all the mucous membranes in the nose to dry out. Low relative humidity does not simply occur in the winter. II also characterises air-conditioned buildings, aircraft and cars throughout the year. Prescriptions must be written on an Authority Prescription Form, and the approval number must be noted on the prescription. Pharmacists cannot dispense the item as a pharmaceutical benefit unless it has been approved by Medicare Australia (indicated by the presence of the approval number).